ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients.
Standard
ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients. / Tachezy, Michael; Zander, Hilke; Marx, Andreas H; Gebauer, Florian; Rawnaq, Tamina; Kaifi, Jussuf T; Sauter, Guido; Izbicki, Jakob R; Bockhorn, Maximilian.
in: J SURG RES, Jahrgang 170, Nr. 2, 2, 01.10.2011, S. 226-232.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients.
AU - Tachezy, Michael
AU - Zander, Hilke
AU - Marx, Andreas H
AU - Gebauer, Florian
AU - Rawnaq, Tamina
AU - Kaifi, Jussuf T
AU - Sauter, Guido
AU - Izbicki, Jakob R
AU - Bockhorn, Maximilian
N1 - Copyright © 2011 Elsevier Inc. All rights reserved.
PY - 2011/10/1
Y1 - 2011/10/1
N2 - BACKGROUND: Activated leukocyte cell adhesion molecule (ALCAM, CD166) is a cell membrane protein that is aberrantly expressed in different tumors, including pancreatic neuroendocrine tumors (PNET). The aim of this study was to determine the expression of ALCAM in PNET to learn more about the prevalence and clinical significance of ALCAM expression in PNET.METHODS: Primary tumors (n = 38) and corresponding lymph node (n = 5) and liver metastases (n = 9) of patients with PNET, treated at the University Medical Center Hamburg-Eppendorf between 1993 and 2006, were analyzed via ALCAM immunohistochemistry in a tissue microarray format. The results were correlated with clinical and histopathologic data, including the WHO classification of PNET.RESULTS: The majority of primary (74%) and secondary (50%) lesions of PNET showed strong ALCAM expression. Immunohistochemistry of primary tumors revealed an association between high ALCAM expression and the hormone production status of the tumor (P = 0.037), and an inverse correlation with metastasis status (P = 0.041) and tumor size (cut off level 2 cm, P = 0.013). Elevated ALCAM expression was a significant positive prognostic factor for recurrence-free (P = 0.002) and disease-specific survival (P = 0.009) in Kaplan-Meier survival analysis (log rank test).CONCLUSIONS: ALCAM is abundantly expressed in PNET and decreased expression is significantly associated with poor prognosis. ALCAM may be a potential marker for risk prediction in patients diagnosed with PNET. Further studies with larger patient collectives are required to validate the results of this study and investigate the functional role of ALCAM in PNET.
AB - BACKGROUND: Activated leukocyte cell adhesion molecule (ALCAM, CD166) is a cell membrane protein that is aberrantly expressed in different tumors, including pancreatic neuroendocrine tumors (PNET). The aim of this study was to determine the expression of ALCAM in PNET to learn more about the prevalence and clinical significance of ALCAM expression in PNET.METHODS: Primary tumors (n = 38) and corresponding lymph node (n = 5) and liver metastases (n = 9) of patients with PNET, treated at the University Medical Center Hamburg-Eppendorf between 1993 and 2006, were analyzed via ALCAM immunohistochemistry in a tissue microarray format. The results were correlated with clinical and histopathologic data, including the WHO classification of PNET.RESULTS: The majority of primary (74%) and secondary (50%) lesions of PNET showed strong ALCAM expression. Immunohistochemistry of primary tumors revealed an association between high ALCAM expression and the hormone production status of the tumor (P = 0.037), and an inverse correlation with metastasis status (P = 0.041) and tumor size (cut off level 2 cm, P = 0.013). Elevated ALCAM expression was a significant positive prognostic factor for recurrence-free (P = 0.002) and disease-specific survival (P = 0.009) in Kaplan-Meier survival analysis (log rank test).CONCLUSIONS: ALCAM is abundantly expressed in PNET and decreased expression is significantly associated with poor prognosis. ALCAM may be a potential marker for risk prediction in patients diagnosed with PNET. Further studies with larger patient collectives are required to validate the results of this study and investigate the functional role of ALCAM in PNET.
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Young Adult
KW - Immunohistochemistry
KW - Lymphatic Metastasis
KW - Prognosis
KW - Kaplan-Meier Estimate
KW - Tumor Markers, Biological/metabolism
KW - Antigens, CD/metabolism
KW - Cell Adhesion Molecules, Neuronal/metabolism
KW - Fetal Proteins/metabolism
KW - Liver Neoplasms/metabolism/secondary
KW - Neuroendocrine Tumors/metabolism/secondary
KW - Pancreatic Neoplasms/metabolism/pathology
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Young Adult
KW - Immunohistochemistry
KW - Lymphatic Metastasis
KW - Prognosis
KW - Kaplan-Meier Estimate
KW - Tumor Markers, Biological/metabolism
KW - Antigens, CD/metabolism
KW - Cell Adhesion Molecules, Neuronal/metabolism
KW - Fetal Proteins/metabolism
KW - Liver Neoplasms/metabolism/secondary
KW - Neuroendocrine Tumors/metabolism/secondary
KW - Pancreatic Neoplasms/metabolism/pathology
U2 - 10.1016/j.jss.2011.06.002
DO - 10.1016/j.jss.2011.06.002
M3 - SCORING: Journal article
C2 - 21816425
VL - 170
SP - 226
EP - 232
JO - J SURG RES
JF - J SURG RES
SN - 0022-4804
IS - 2
M1 - 2
ER -
